Myriad Genetics Expands MyRisk Test with 15 New Genes for Cancer Care
Myriad Genetics Enhances MyRisk Test with Expanded Gene Panel
Myriad Genetics, Inc. (NASDAQ: MYGN), a notable leader in molecular diagnostics and precision medicine, has made an exciting advancement by adding 15 clinically actionable genes to its MyRisk® Hereditary Cancer Test. This enhancement reflects a strong commitment to addressing the evolving clinical needs of healthcare providers and patients alike.
New Genes in the MyRisk Panel
The MyRisk Test, known for being a premier gold standard in germline testing, has now expanded its gene coverage significantly. This update aligns with several authoritative guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). The new additions bring the total number of genes analyzed in the MyRisk panel to 63, which spans over 11 distinct cancer types.
Importance of Gene Actionability
These newly incorporated genes are not only relevant but are strongly linked with cancer risk and clinical actionability. This means that their inclusion enhances the clinical insights available for patient care, ultimately leading to better treatment outcomes. Each carefully selected gene offers meaningful information that can guide health professionals in making informed treatment decisions for patients.
Commitment to Patient Care
Dr. Dale Muzzey, Chief Scientific Officer at Myriad Genetics, emphasized the company's dedication to elevating patient care by stating, “While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels.” This focus on actionable insights underlines the importance of testing for genes that influence treatment decisions, reinforcing the core mission of Myriad with the MyRisk Test.
How the MyRisk Test Works
The MyRisk Test is strategically designed to offer clinical value throughout the entire cancer care continuum. It assists healthcare providers in making treatment choices, planning surveillance strategies, and assessing family risk across various types of cancer. The convenience of ordering and reviewing MyRisk Test results can be done directly through paper requisition forms, the Myriad patient portal, and compatibility with several electronic medical record systems, including EPIC and OncoEMR.
Future of Genetic Testing
As advancements continue to emerge in the field of genetic testing, Myriad Genetics remains steadfast in its commitment to adapt and expand its offerings. By staying at the forefront of clinical guidelines and seeking to improve patient outcomes, Myriad positions itself as a leader in precision medicine, enhancing the capabilities of healthcare professionals in delivering quality patient care.
Accessing Gene Management Information
Healthcare providers and interested parties can access the complete list of genes and the related medical management recommendations through the Myriad gene table. This resource serves as a vital tool for understanding the implications of the new genes added to the MyRisk Test.
About Myriad Genetics
Myriad Genetics is an innovative company dedicated to advancing the science of molecular diagnostic testing and precision medicine. It helps patients and healthcare providers by offering molecular tests that evaluate the risk of disease development and progress. Myriad’s focus on improving healthcare delivery and reducing costs makes it a pivotal player in the field.
Frequently Asked Questions
What is the MyRisk Test?
The MyRisk Test is a hereditary cancer test developed by Myriad Genetics that evaluates genetic risk for various cancers.
What new genes were added to the MyRisk Test?
Fifteen new clinically actionable genes related to cancer risk have been added to enhance the insights provided by the MyRisk Test.
How does this expansion benefit patient care?
The new genes included in the MyRisk Test offer healthcare providers clearer actionability and guidance for treatment decisions, ultimately improving patient outcomes.
Is the MyRisk Test easy for doctors to order?
Yes, healthcare professionals can order the MyRisk Test easily through multiple platforms including paper requisition forms and electronic medical records.
Where can I find more information about Myriad Genetics?
More information can be accessed through the Myriad Genetics official website, which provides details on their tests and services.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.